Cooper Companies, Inc. (The) (NYSE:COO)‘s stock had its “buy” rating restated by BMO Capital Markets in a note issued to investors on Friday. They currently have a $272.00 target price on the medical device company’s stock. BMO Capital Markets’ price objective would indicate a potential upside of 15.17% from the stock’s current price.

Other research analysts also recently issued reports about the company. Zacks Investment Research upgraded Cooper Companies, Inc. (The) from a “hold” rating to a “buy” rating and set a $270.00 target price on the stock in a research note on Tuesday, June 6th. Jefferies Group LLC reiterated a “buy” rating and issued a $250.00 target price (up from $220.00) on shares of Cooper Companies, Inc. (The) in a research note on Saturday, June 3rd. Stifel Nicolaus lifted their target price on Cooper Companies, Inc. (The) from $220.00 to $231.00 and gave the company a “buy” rating in a research note on Friday, June 2nd. BidaskClub downgraded Cooper Companies, Inc. (The) from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. Finally, Cleveland Research reiterated a “buy” rating on shares of Cooper Companies, Inc. (The) in a research note on Tuesday, August 22nd. Five analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $245.89.

Shares of Cooper Companies, Inc. (NYSE:COO) opened at 236.18 on Friday. The firm has a market cap of $11.54 billion, a P/E ratio of 35.41 and a beta of 0.61. The company’s 50 day moving average price is $246.43 and its 200-day moving average price is $221.27. Cooper Companies, Inc. has a 12-month low of $158.73 and a 12-month high of $256.39.

Cooper Companies, Inc. (The) (NYSE:COO) last announced its earnings results on Thursday, August 31st. The medical device company reported $2.64 earnings per share for the quarter, beating the consensus estimate of $2.58 by $0.06. Cooper Companies, Inc. (The) had a return on equity of 15.88% and a net margin of 16.02%. The company had revenue of $556 million for the quarter, compared to the consensus estimate of $552.32 million. During the same period last year, the business posted $2.30 EPS. The company’s revenue was up 8.0% on a year-over-year basis. On average, equities research analysts anticipate that Cooper Companies, Inc. will post $9.64 EPS for the current year.

WARNING: This article was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was illegally copied and republished in violation of US & international copyright & trademark law. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/09/02/cooper-companies-inc-the-coo-earns-buy-rating-from-bmo-capital-markets.html.

In other news, Director Stanley Md Zinberg sold 816 shares of the firm’s stock in a transaction that occurred on Wednesday, June 7th. The stock was sold at an average price of $243.14, for a total value of $198,402.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Carol R. Kaufman sold 44,092 shares of the firm’s stock in a transaction that occurred on Thursday, June 8th. The shares were sold at an average price of $242.81, for a total value of $10,705,978.52. Following the completion of the sale, the executive vice president now directly owns 60,419 shares of the company’s stock, valued at $14,670,337.39. The disclosure for this sale can be found here. Insiders sold a total of 67,331 shares of company stock valued at $16,400,454 over the last three months. Insiders own 1.60% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. YorkBridge Wealth Partners LLC boosted its stake in Cooper Companies, Inc. (The) by 18.5% in the first quarter. YorkBridge Wealth Partners LLC now owns 520 shares of the medical device company’s stock valued at $105,000 after buying an additional 81 shares in the last quarter. Advisory Services Network LLC boosted its stake in Cooper Companies, Inc. (The) by 30.6% in the second quarter. Advisory Services Network LLC now owns 457 shares of the medical device company’s stock valued at $109,000 after buying an additional 107 shares in the last quarter. Archford Capital Strategies LLC boosted its stake in Cooper Companies, Inc. (The) by 116.7% in the first quarter. Archford Capital Strategies LLC now owns 674 shares of the medical device company’s stock valued at $135,000 after buying an additional 363 shares in the last quarter. Acrospire Investment Management LLC boosted its stake in Cooper Companies, Inc. (The) by 50.0% in the second quarter. Acrospire Investment Management LLC now owns 600 shares of the medical device company’s stock valued at $144,000 after buying an additional 200 shares in the last quarter. Finally, Penserra Capital Management LLC boosted its stake in Cooper Companies, Inc. (The) by 9.5% in the first quarter. Penserra Capital Management LLC now owns 782 shares of the medical device company’s stock valued at $156,000 after buying an additional 68 shares in the last quarter. 96.09% of the stock is owned by institutional investors and hedge funds.

About Cooper Companies, Inc. (The)

The Cooper Companies, Inc is a global medical device company. The Company operates through two business units: CooperVision, Inc and CooperSurgical, Inc CooperVision offers soft contact lenses for the vision correction market. CooperVision develops, manufactures and markets a range of single-use, two-week and monthly contact lenses.

Analyst Recommendations for Cooper Companies, Inc. (The) (NYSE:COO)

Receive News & Stock Ratings for Cooper Companies Inc. (The) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies Inc. (The) and related stocks with our FREE daily email newsletter.